CA2706082C - Nitric oxide donor compounds - Google Patents

Nitric oxide donor compounds Download PDF

Info

Publication number
CA2706082C
CA2706082C CA2706082A CA2706082A CA2706082C CA 2706082 C CA2706082 C CA 2706082C CA 2706082 A CA2706082 A CA 2706082A CA 2706082 A CA2706082 A CA 2706082A CA 2706082 C CA2706082 C CA 2706082C
Authority
CA
Canada
Prior art keywords
compound
group
pharmaceutically acceptable
acceptable salts
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2706082A
Other languages
English (en)
French (fr)
Other versions
CA2706082A1 (en
Inventor
Nicoletta Almirante
Silvia Stefanini
Laura Storoni
Fabio Nicoli
Julio Lazaro Padron
Stefano Biondi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox Science Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Science Ireland Ltd filed Critical Nicox Science Ireland Ltd
Publication of CA2706082A1 publication Critical patent/CA2706082A1/en
Application granted granted Critical
Publication of CA2706082C publication Critical patent/CA2706082C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2706082A 2008-02-07 2009-01-15 Nitric oxide donor compounds Active CA2706082C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US694608P 2008-02-07 2008-02-07
US61/006,946 2008-02-07
PCT/EP2009/050416 WO2009098113A1 (en) 2008-02-07 2009-01-15 Nitric oxide donor compounds

Publications (2)

Publication Number Publication Date
CA2706082A1 CA2706082A1 (en) 2009-08-13
CA2706082C true CA2706082C (en) 2017-10-03

Family

ID=40445685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2706082A Active CA2706082C (en) 2008-02-07 2009-01-15 Nitric oxide donor compounds

Country Status (6)

Country Link
US (1) US8003811B2 (enExample)
EP (1) EP2238143B1 (enExample)
JP (1) JP5441928B2 (enExample)
CA (1) CA2706082C (enExample)
ES (1) ES2393049T3 (enExample)
WO (1) WO2009098113A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
KR101794363B1 (ko) 2009-12-11 2017-11-06 디에스엠 아이피 어셋츠 비.브이. 반추동물에서의 메탄 방출을 감소시키고/감소시키거나 반추동물 수익성을 개선시키기 위한 사료중의 니트로옥시 알칸산 및 이의 유도체
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
US10154981B2 (en) 2011-05-26 2018-12-18 Dsm Ip Assets B.V. Use of a feed composition for reducing methane emission in ruminants, and/or to improve ruminant performance
CA2902009A1 (en) * 2013-03-05 2014-09-12 Archer Daniels Midland Company Isohexide monotriflates and process for synthesis thereof
JP6306148B2 (ja) * 2013-04-18 2018-04-04 ニコックス サイエンス アイルランド 点眼用のキノン系一酸化窒素供与性化合物
US9738773B2 (en) * 2014-08-08 2017-08-22 Central Michigan University Flame retardants from renewable resources
CA2968010A1 (en) * 2014-11-19 2016-05-26 Nicox S.A. Combinations of prostaglandins and nitric oxide donors
EP3088388A1 (en) 2015-04-30 2016-11-02 NicOx S.A. Nitric oxide donating derivatives of prostaglandins
WO2018224419A1 (en) * 2017-06-06 2018-12-13 Nicox S.A. Nitric oxide donating isomannide derivatives
CN112566670B (zh) 2018-08-06 2024-11-12 尼科斯股份有限公司 一氧化氮释放第5型磷酸二酯酶抑制剂
US11779560B2 (en) * 2020-03-28 2023-10-10 Coeurative, Inc. Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149521A (ja) * 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
DE3831949A1 (de) 1988-09-20 1990-03-22 Mack Chem Pharm Arzneimittel
ES2142773B1 (es) * 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
IE20070934A1 (en) * 2007-12-21 2009-06-24 Trinity College Dublin Efficient aspirin prodrugs

Also Published As

Publication number Publication date
US8003811B2 (en) 2011-08-23
CA2706082A1 (en) 2009-08-13
JP2011511022A (ja) 2011-04-07
EP2238143A1 (en) 2010-10-13
JP5441928B2 (ja) 2014-03-12
US20100249189A1 (en) 2010-09-30
EP2238143B1 (en) 2012-08-15
ES2393049T3 (es) 2012-12-18
WO2009098113A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
EP2238143B1 (en) Nitric oxide donor compounds
ES2861393T3 (es) Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones
EP4186903A1 (en) Quinazoline compound
CA2641138C (fr) Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique
US6858632B2 (en) Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance
US4559351A (en) Dihydropyridine derivatives of 1,4:3,6-dianhydrohexitols
EP4134366A1 (en) 3-azabicycloalkyl derivative and pharmaceutical composition containing same
Hafez et al. Synthesis, biological and medicinal significance of S-glycosido-thieno [2, 3-d]-pyrimidines as new anti-inflammatory and analgesic agents
Cheng et al. Synthesis of oleanolic acid dimers as inhibitors of glycogen phosphorylase
CN108084233B (zh) 一种糖基修饰的丁苯酞开环衍生物的制备方法及医药用途
EP3805230B1 (en) Thieno[2,3-c]pyridazin-4(1h)-one derivative and application thereof
US6180664B1 (en) Pentaerythritol derivatives, their production and use and intermediates for their synthesis
Kim et al. Importance of sulfonylimidazolidinone motif of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxicity: synthesis of 2-benzoyl-4-phenyl [1, 2, 5] thiazolidine-1, 1-dioxides and their cytotoxcity
JP5994059B2 (ja) 抗マラリア活性を有するアザアルテミシニン誘導体及びその製造方法
SK169599A3 (en) Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same
US5120737A (en) Hexitol derivatives
EP4541803A1 (en) Cyclopentyl adenosine derivative and pharmaceutical use thereof
RO133477A2 (ro) Analogi alifatici de izoniazidă ()substituită
WO2022260648A1 (en) Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions
HK1039125A (en) Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance
HK1030608A (en) Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same
ITMI20111081A1 (it) Nuovi diossolenilmetil derivati che rilasciano no

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140114

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250715

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251105